SEP-363856

SEP-363856 Uses, Dosage, Side Effects, Food Interaction and all others data.

SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A).

SEP-363856 was developed by Sunovion pharmaceuticals. An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia. Negative symptoms of schizophrenia are more difficult to treat and may include flattened affect, anhedonia, and social withdrawal. Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug.

Trade Name SEP-363856
Generic SEP-363856
Type
Formula C9H13NOS
Weight Average: 183.27
Monoisotopic: 183.071785217
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
SEP-363856
SEP-363856

Innovators Monograph

You find simplified version here SEP-363856

*** Taking medicines without doctor's advice can cause long-term problems.
Share